OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on February 22, 2011. The report discloses the entry into a material definitive agreement regarding the company's credit facilities.
Key Financial Metrics
- Line of Credit: $12,000,000 (renewed).
- Interest Rate: 11% annual rate, compounded quarterly on outstanding borrowings.
- Outstanding Borrowings: $0 as of the report date.
- Collateral: All personal property of the company, excluding intellectual property.
- Liquidity: The filing does not provide specific cash flow, revenue, or profit metrics.
Material Changes
The company entered into Amendment No. 2 to its Credit Agreement with The Frost Group, LLC. This amendment renewed the $12,000,000 line of credit, which had previously expired on January 11, 2011. The new expiration date is March 31, 2012. The terms remain substantially the same as the prior agreement.
Management Commentary and Related Parties
The credit agreement is with The Frost Group, LLC, a private investment group controlled by Dr. Phillip Frost, M.D., the Company's Chairman and CEO. Other members of The Frost Group include Dr. Jane Hsiao (Vice Chairman and CTO), Dr. Rao Uppaluri (CFO), and Mr. Steven D. Rubin (Executive Vice President-Administration and Director).
Investor Verification Checklist
- Verify the total outstanding debt and interest expense in the most recent 10-Q or 10-K filings.
- Confirm the status of the company's personal property assets pledged as collateral.
- Review the related party transaction disclosures to understand the full scope of the relationship with The Frost Group.
- Check for any subsequent borrowings under this renewed line of credit.